-
Zelnorm Approved By FDA (Again) In 2019 – Despite Zelnorm Being Removed From Market In 2007 For Safety Concerns
Concerns About Potential Cardiovascular Safety Signal As Well As Suicidal Ideation And Behavior Were Involved With Zelnorm Recall (Posted by Tom Lamb at DrugInjuryWatch.com) In October 2018 we wrote this article, “Waiting…
-
Lymphoma Cancer Associated With Breast Implants: FDA Advisory Committee Meeting March 2019
Warning Letters Sent To Companies Mentor Worldwide And Sientra For Breast Implants Safety Monitoring Failures (Posted by Tom Lamb at DrugInjuryWatch.com) Albeit a bit off-topic for the general focus of this Drug…
-
Gadolinium Contrast Agents Side Effects: Medical Literature Review, September 2018 – February 2019
Researchers Continue To Investigate Gadolinium Deposition Disease (GDD) Following Gadolinium-Based Contrast Agents Injections (Posted by Tom Lamb at DrugInjuryWatch.com) In recent years it has been recognized that the gadolinium contained in certain…
-
Xeljanz Recommended Dosage For Ulcerative Colitis Patients May Increase Risk Of Pulmonary Embolism
FDA Is Reviewing Safety Of Xeljanz 10 mg Twice-Daily Dose Of This JAK Inhibitor, According to February 2019 News Reports (Posted by Tom Lamb at DrugInjuryWatch.com) UPDATE: FDA Drug Safety Communication: "Safety…
-
Breast Implants Lymphoma Cancer Cases Updates For United States And Canada: February 2019
Additional Cases Of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) Reported To FDA, Health Canada (Posted by Tom Lamb at DrugInjuryWatch.com) For our first 2019 update about breast implant-associated anaplastic large cell…